Search bioRxiv⌕ Search

Biology subjects

Picketts, D.

Publications and source records attributed to Picketts, D..

2 recordsLinked to original sources

An allelic series reveals the genetic requirement for Adnp in cortical neurogenesis and learning behavior

Transcriptional regulators and chromatin remodellers are among the most important risk gene categories across the genetic landscape of neurodevelopmental disorders (NDDs). The zinc finger and homeodomain transcription factor ADNP is prominently associated with Helsmoortel-Van der Aa Syndrome (HVDAS), which is characterized by intellectual disability and autism spectrum disorder. Heterozygous frameshifting mutations account for the majority of HVDAS mutations, but it remains unclear how HVDAS mutations affect ADNP dosage, and how dosage in turn relates to neurodevelopmental and behavioral phenotypes. Here, we compared an allelic series of Adnp cKOs and germline heterozygotes. Using a conditional allele, we first deleted Adnp throughout the neural tube using Nestin-Cre. At E15.5, cKO brains exhibited altered upper-layer neuron production. However, AdnpNestincKOs exhibited perinatal lethality, precluding further behavioral characterization. Next, we compared germline heterozygotes (gHets) versus cKOs generated using the Emx1-Cre driver. We found that AdnpDel/+and AdnpL822fs6/+ gHets exhibited cortical hypoplasia that was quantitatively identical, albeit less severe in comparison to AdnpEmxcKOs. In behavioral testing, AdnpEmx cKOs accordingly exhibited the strongest phenotypes, including hallmarks of elevated anxiety. However, both AdnpEmx cKOs and AdnpL822fs6/+ gHets exhibited remarkably similar sex-specific deficits in learning during Morris Water Maze testing. Taken together, our work suggests that cortical growth and learning represent core phenotypes shared across Adnp mutant models irrespective of dosage. Moreover, since Adnp mutant phenotypes closely correspond with our prior findings in Chd4 mutants, our results collectively suggest that Adnp regulates behavior via the ChAHP chromatin remodelling complex.

neuroscience↗

Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma

The MYC proto-oncogenes (c-MYC, MYCN, MYCL) are among the most deregulated oncogenic drivers in human malignancies including high-risk neuroblastoma, 50% of which are MYCN-amplified. Genetically engineered mouse models (GEMMs) based on the MYCN transgene have greatly expanded the understanding of neuroblastoma biology and are powerful tools for testing new therapies. However, a lack of c-MYC-driven GEMMs has hampered the ability to better understand mechanisms of neuroblastoma oncogenesis and therapy development given that c-MYC is also an important driver of many high-risk neuroblastomas. In this study, we report two transgenic murine neuroendocrine models driven by conditional c-MYC induction in tyrosine hydroxylase (Th) and dopamine {beta}-hydroxylase (Dbh)-expressing cells. c-MYC induction in Th-expressing cells leads to a preponderance of Pdx1+ somatostatinomas, a type of pancreatic neuroendocrine tumor (PNET), resembling human somatostatinoma with highly expressed gene signatures of {delta} cells and potassium channels. In contrast, c-MYC induction in Dbh-expressing cells leads to onset of neuroblastomas, showing a better transforming capacity than MYCN in a comparable C57BL/6 genetic background. The c-MYC murine neuroblastoma tumors recapitulate the pathologic and genetic features of human neuroblastoma, express GD2, and respond to anti-GD2 immunotherapy. This model also responds to DFMO, an FDA-approved inhibitor targeting ODC1, which is a known MYC transcriptional target. Thus, establishing c-MYC-overexpressing GEMMs resulted in different but related tumor types depending on the targeted cell and provide useful tools for testing immunotherapies and targeted therapies for these diseases.

cancer biology↗